Enterococci are the third most common etiologic agent of infective endocarditis worldwide after staphylococci and streptococci and cause 10-15% of cases 1 . Enterococcal infections are increasingly relevant, especially among the elderly and patients with comorbid conditions in the healthcare setting 2, 3 . Approximately 90% of cases of enterococcal endocarditis are caused by
Enterococcus faecalis, with less than 5% caused by Enterococcus faecium 2, 3 . The morbidity and mortality of enterococcal endocarditis is high. The percentage of patients requiring cardiac surgery (42%) and the 1-year mortality rate (29%) have remained almost unchanged for the last 30 years, and recent data show that they may even be increasing 3 .
This worrying picture is worsened by the increase in resistance to classic antimicrobials, especially to high-level aminoglycoside (HLAR). However, American Heart Association (AHA) guidelines 4 have not modified their antibiotic recommendations on non-HLAR strains for almost 6 decades, and no randomized clinical trials (RCT) support current evidence. Since the empirical use of ampicillin+streptomycin has proven efficacious 5 and synergistic (increased cell membrane permeability to aminoglycosides induced by betalactams in vitro with enterococci) 6 , the efficacy of combining a betalactam with an aminoglycoside is unquestionable. The latest AHA guidelines maintain penicillin or ampicillin (or vancomycin in case of allergy to betalactams) plus gentamicin as the combination of choice for E. faecalis infective endocarditis (EFIE) caused by non-HLAR strains 4 . Recommendations on length of treatment have also remained unchanged since the 1980s 7 , namely, 4 weeks for uncomplicated native-valve endocarditis and 6 weeks for prosthetic-valve endocarditis (PVE) and patients with a >3-month history of symptoms before diagnosis 4 . The gentamicin dose schedule (3 mg/kg per 24 h IV/IM in 3 equally spaced doses) has also remained unchanged for 2 decades.
In this issue of Circulation, Dahl et al 8 reported on the efficacy and safety of especially to high-level aminoglycoside (HLAR). However, American Heart As sso soci ci iat atio io on n n (A (A (AHA HA) ) guidelines 4 have not modified their antibiotic recommendations on non-HLAR strains for almost 6 de de eca ca cade de des, s, a a and n n n no o o r ra randomized clinical trials (RC C CT T T) support curren en nt t ev vid id ide en ence. Since the empirical u use of o ampicil lli li in+ n n+s stre rept pto o omy my m ci ci cin n n ha ha as s pr prov ov ven e e eff ff ficac c cio ous s 5 5 5 a and nd d s syn yne e erg gi gist stic ic ic ( (in inc c cre re reas ased ed d c cel el ell l l me me memb mb mbr ra rane ampicillin+short-course gentamicin for treating non-HLAR EFIE in Denmark 8 . Notably, renal function, expressed using glomerular filtration rate (GFR), was also similar in both groups before initiation of treatment. All patients received gentamicin 3 mg/kg, trough levels were monitored in all cases, and dose schedule did not differ significantly between the 2 HLAR), the omission of the type of aminoglycosides used, the low percentage of of f pat at a ie ie ent nt nts s s wi wi with th ymptoms for >3 months (only 5%), the short follow-up (53% at 3 months), and the fact that no an nal al alys ys ysis is is o o of f f an an ntimi mi mic cr crobial-associated adverse even en ents ts is provided. This study provides novel data on non-HLAR EFIE and aminoglycoside use. First, it
demonstrates that 2 weeks of gentamicin was as efficacious as and less nephrotoxic than 4-6
weeks. Remarkably, short-course gentamicin was also safe and efficacious for E. faecalis PVE.
Second, it shows that QD gentamicin was clinically efficacious. AHA guidelines recommend a schedule comprising 3 equally spaced doses (TID) of gentamicin 4 , and European Society of Cardiology (ESC) guidelines (based on experimental data) recommend a BID or TID regimen 11 .
However, these findings are open to debate. The study by Hessen et al 12 showed that the postantibiotic effect of QD gentamicin did not achieve bactericidal concentrations in vegetations of rats with EFIE treated with penicillin and gentamicin; the authors suggested shortening the dosing interval in order to maintain antibiotic levels over the minimum inhibitory concentration.
Subsequent results are consistent with these findings. However, using a human-like pharmacokinetic model, Gavaldà et al 13 found that the therapeutic efficacy of ampicillin+gentamicin was not significantly affected by the gentamicin dosing interval, with QD dosing similar to TID dosing 13 . The study by Dahl et al 8 is the first to provide data from a large number of patients treated with a QD gentamicin schedule. Seventy-two (86%) of the 84 patients received a QD regimen, only 10 received TID, and 2 BID, with no association between poor outcome and dosing interval. Third, the authors provide evidence that nephrotoxicity was Second, it shows that QD gentamicin was clinically efficacious. AHA guidelines s rec ec ecom m mme me mend nd nd a a chedule comprising 3 equally spaced doses (TID) of gentamicin 4 , and European Society of associated with the duration of gentamicin therapy, because at 2 weeks the decrease in GFR was very small and similar in both cohorts (P=0.65). However, at discharge, patients who received the standard gentamicin course had a significantly greater decrease in GFR (11 vs. 1 ml/min, P=0.008). Therefore, this finding is especially relevant, since the typical EFIE patient is older, with high rates of chronic renal failure (CRF) and a high risk of rapid renal impairment. The use of GFR as a measure of renal function is a wise choice, since it accurately reflects the impact of treatment on kidney integrity, unlike the widely used creatinine value, which can be easily America and d 38 38 38% % % in in in t t the he he res es est t of of of t t the he h w w wor or rld ld ld 3 3 3 . . and 51% non-HLAR strains) treated with ampicillin (2 g/4 h) and ceftriaxone (2 g/12 h) 18 .
Clinical cure rates were 71% and 73%, respectively, with 5% relapses. The study by Fernández-Hidalgo et al 14 was an observational, nonrandomized, comparative multicenter cohort study including 159 patients treated with ampicillin+ceftriaxone (31% HLAR strains) and 87 patients treated with ampicillin+gentamicin (all non-HLAR strains) ( Table 1) . Gentamicin was administered for as long as ampicillin in 31 patients (36%); it was stopped after a median (IQR) of 23 (14-34) days in 34 patients with no adverse events. In 20 of the 22 patients in whom gentamicin was withdrawn because of adverse events (20 patients experienced renal failure), the median length of treatment was 14-15 days. The gentamicin schedule was QD, BID, TID, or unknown in 43%, 7%, 43%, and 7%, respectively. Overall, no differences were found between the 2 groups regarding treatment failure, mortality during treatment or at 3 months of follow-up, and relapses. However, a higher proportion of patients receiving ampicillin+gentamicin switched or stopped gentamicin owing to renal failure (0 vs. 23%; P<0.001). At baseline, more patients in the ampicillin+ceftriaxone group had CRF (P=0.004), and although an outcome analysis based on the presence of HLAR was not performed, ampicillin+ceftriaxone proved effective in both strains and was globally safer than ampicillin+gentamicin for 4-6 weeks. AHA 4 and ESC 11 guidelines consider ampicillin+ceftriaxone administered for at least 8 weeks a potential antibiotic therapy for EFIE with HLAR to both streptomycin and gentamicin; however, neither the AHA nor the ESC considers this combination the treatment of choice for non-HLAR EFIE. We believe the study by Fernández-Hidalgo et al confirms that this combination given for a median of 6 weeks is an effective therapy for both HLAR and non-HLAR EFIE and that it was safer than 4 to considering that the median length of therapy with gentamicin in those patients who developed renal failure was 2 weeks. This study does not clarify if 4 weeks of ampicillin+ceftriaxone would be effective against uncomplicated native valve EFIE.
Both studies are subject to limitations. The most important is they are not randomized controlled trials. The study by Dahl et al 8 is also limited by the small sample size of both cohorts and insufficient power; therefore, the results need to be interpreted with caution. In the study by Fernández-Hidalgo et al 14 , most cases were retrospectively collected, with the consequent potential biases in the choice of treatment combination, which depends on the existence of baseline CRF, and in when antibiotic therapy was stopped and switched in those patients on gentamicin who developed renal failure. In 10 patients, gentamicin was switched to ceftriaxone after a median (IQR) length of 15 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] days. In addition, the gentamicin schedule was not the same for all patients, and renal impairment was not assessed using GFR. In the study by Dahl et al, the exclusion of 5 patients undergoing hemodialysis could represent another bias, since this is a classic risk factor for EFIE, and no adverse events other than renal failure secondary to aminoglycoside treatment were assessed. Both studies are affected by referral bias, which is remarkable in the study by Fernández-Hidalgo et al, with an initial indication for cardiac surgery in 60% of cases. In addition, low numbers of patients with more than 3 months of symptoms might also be considered a limitation, although this might only reflect a higher clinical suspicion of IE resulting in an earlier diagnosis. Finally, the potential risk of colonization or superinfection by drug-resistant bacteria was not assessed. It is well known that prolonged therapy with cephalosporin is a risk factor for infection by vancomycin-resistant enterococci or Clostridium difficile 19 .
In conclusion, both publications make an enormous contribution to improving the gentamicin who developed renal failure. In 10 patients, gentamicin was switched d d to o o cef ef eftr tr tria ia iaxo xo xone n after a median (IQR) length of 15 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] days. In addition, the gentamicin schedule was not the same fo or r al al all l l p pa pati ti tien en e t t ts, an an and d d renal impairment was not ass ss sses ess sed using GFR. R. R In n th th the e e study by Dahl et al, the ex xcl cl lus u ion of 5 5 p pa at a i i ient nts s u un unde de derg rg rgoi oing ng g h h hem em mo o odia aly lysis co co cou uld d d r re repr pr res s sen ent t t a an not othe h h r r bi bia as as, si sinc nc nce e th th his i i i i is s a a a cl las as assi si ic c c ri risk sk k f f fa ac acto tor f fo for r EF EF FIE IE, a an and d d no no no a adv dv ver er rse se se e ev v ven en e t ts s o o oth h her er r t t tha ha han n re re r n na nal l l fa fa fail il lur ure e se se eco co ond nd dar ar ary y y to to o aminoglycosi side de de t tre re reat at a me me ment n w w wer er e e e as as asse se ess s ed ed ed. . Bo Bo Both th th s st t tud ud udie ie ies s ar ar are e e af af affe fe ect ct cted ed e b b by y y re re refe fe ferr rr rral al b b bia ia ias, s, s, w w whi h ch is t t t efficacy and safety of treatment of EFIE. In patients with EFIE that is highly resistant to both streptomycin and gentamicin, ampicillin+ceftriaxone for 6 weeks should be the regimen of choice. In the case of patients with non-HLAR EFIE, there are 2 options: if treatment with ampicillin+gentamicin is chosen, gentamicin can be shortened to 2 weeks and simplified to QD dosing in order to avoid nephrotoxicity; conversely, ampicillin+ceftriaxone is also very safe and effective. Unfortunately, efforts to perform a multinational randomized controlled trial ND = No data; NA = Not applicable.* All patients were treated with gentamicin 3 mg/kg (up to 240 mg/day) administered IV 1-3 times daily at the discretion of the treating physician and adjusted according to renal function when necessary.** Ceftriaxone was given at 2 g/12 h IV with ampicillin 2 g/4h IV (adjusted according to renal function when necessary) for 6 weeks. ¶ Mean (SD); ¶ ¶ Rash/fever and leukopenia in 1 case each in the ampicillin+ceftriaxone group; vestibular toxicity in 2 cases in the ampicillin+gentamicin group. 
